Neurocrine Biosciences (NBIX) and Abbott (ABT) Team Up to Commercialize Novel Endometriosis/Uterine Fibroid Drug Elagolix
Abbott, www.abbott.com - one of the undisputed global health care leaders with proficiencies in pharmaceuticals, nutritionals, diagnostics and devices, and Neurocrine Biosciences, Inc. (NBIX), www.neurocrine.com – the biopharma developer focused on endocrine and neurological disease/disorders, announced entry into a collaborative agreement for developing and bringing the new endometriosis-related pain treatment, Elagolix, to full commercialization. Elagolix is a gonadotropin-releasing hormone (GnRH) antagonist which inhibits receptors in the pituitary gland, giving it a unique functionality as an estrogen delimiter which is able to relieve symptoms without the typical adverse side effects. Elagolix is a first-in-class oral 8 preparation which has shown pain…